TCL Archive Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate April 25, 2014
TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive In Brief: Baque Heads Cancer Control Science Programs; Joftes, Davignon T Retire; Schepartz Returns September 29, 1989